SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

This trial compares two types of targeted radiation therapy — SBRT (stereotactic body radiotherapy, a very precise high-dose technique) versus standard hypofractionated radiation — for men with prostate cancer that has come back after surgery, with or without a small number of cancer spread sites. **You may be eligible if...** - You had your prostate removed by surgery and your PSA (a blood marker for prostate cancer) has risen to between 0.1 and 2.0 ng/mL afterward - Your cancer has spread to no more than 5 sites total (oligometastatic) - You have not had prior pelvic radiation or prior hormone therapy with elevated PSA - You are 18 or older and in reasonably good health (ECOG 0–2) **You may NOT be eligible if...** - You have had prior pelvic radiation - You have received hormone therapy and your PSA was 0.1 or higher at that time - You have had a heart attack or severe heart failure in the last 6 months - You have more than 5 sites of cancer spread - You have Crohn's disease or ulcerative colitis affecting the rectum, or a history of urethral stricture Talk to your doctor to see if this trial is right for you.